By Eric Sagonowsky
As criticism of the FDA's convalescent plasma authorization mounted Monday, Commissioner Stephen Hahn, M.D., sought to clear the air. But his defense—and his attempt to correct a misplaced statistic—didn't sit well with some experts.
read more
By Tina Reed
But remove the CARES Act funding from the equation and there's a much more "dire" situation driven by a devastating spring and sluggish return in patient volumes, according to Kaufman Hall's latest report.
read more
By Eric Sagonowsky
It’s been some months since Biogen’s February management conference has been in the news, but as the pandemic drags on, researchers are now linking the early “superspreading event” with tens of thousands of cases in the U.S.—if not more.
read more
By Conor Hale
Qiagen has announced plans to launch a new digital test for COVID-19 antibodies that can run multiple samples at once on a small portable device and deliver results in about 10 minutes.
read more
By Eric Sagonowsky
With leading COVID-19 vaccines already in efficacy testing, U.S. authorities are eyeing a possible emergency use authorization for AstraZeneca’s program before the election, the Financial Times reported Monday. But AstraZeneca hasn’t been involved in those talks, and the company says it's too early to speculate about a green light right now.
read more
By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner
FDA Commissioner Stephen Hahn backpedalled claims on blood plasma's efficacy. Meanwhile, health experts blasted Hahn for "wasting trust" in the agency. Qiagen plans to roll out a digital antibody test before the end of the month. Medtronic's pandemic revenue slump is subsiding. Plus, doctor-sales rep relationships have grown amid the pandemic, a study found.
read more
By Healthcare Staff
Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.
read more
By Nick Paul Taylor
AstraZeneca has started a phase 1 clinical trial of its two-antibody cocktail against COVID-19. The 48-subject trial is set to deliver data later this year and set AstraZeneca up to evaluate the protective and therapeutic effect of the drug in larger phase 2 and 3 studies.
read more
By Beth Snyder Bulik
Among the many shifts wrought by the COVID-19 pandemic is the relationship between pharma sales reps and physicians. But that might be a good thing. A new Accenture study has actually found plenty of pandemic positives for pharma reps, including doctors with more time to learn about drugs and more inquiries on support services and financial help.
read more
By Robert King
Sutter Health posted an $857 million loss in the first half of the year as operations hit a major decline due to the COVID-19 pandemic.
read more
By Robert King
Mayo Clinic has weathered a sharp drop in patient volume to generate $154 million in net operating income in the second quarter of the year.
read more
By Conor Hale
Over the past quarter, Medtronic’s net income dropped nearly 44% compared to the same period last year—but that still outpaced what many expected, considering the wide-ranging effects of the coronavirus pandemic.
read more
By Ben Adams
Californian siteless trial specialist Science 37 is joining forces with trial data collector ERT to grab the same high-quality data in a virtual model as it would in a traditional model.
read more
